Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Endo International plc (NASDAQ: ENDP) announced in an

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

8-K filing on Wednesday that it plans on terminating its commercial supply and license agreements with VIVUS, Inc. (NASDAQ: VVUS) related to its right to commercialize Avanafil.Endo International received exclusive rights to commercialize Avanafil for any urological disease in the US, Canada, and related territories. The company noted that the effective date of the termination will be June 30, 2016.Shares of Vivus were trading lower by 1 percent at $1.00 early Thursday morning.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsAvanafilEndo Internationalvivus